Rochester,NY 7/3/2009 2:52:31 AM
Mid Day Report - AIS -Israel stocks mixed; Delek gets a boost at Barclays - Sourced WhisperFromWallStreet.com
Antares Pharma Inc
Mid Day Report - AIS -Israel stocks mixed; Delek gets a boost at Barclays - Sourced WhisperFromWallStreet.com
http://whisperfromwallstreet.com is a FREE award winning newsletter that specializes in sending alerts to our subscribers on stocks we think are going to run, why we think so, as well as teaching you how to become a better trader. We scan hundreds of stocks a day to find those that meet our criteria and when we find one, we send you an alert. We have sent out 40 alerts so far in 2009 with an average price gain of over 80%. Please join risk free and see for yourself.
Sign up for our FREE alerts at WhisperfromWallStreet.com
---
Antares Pharma Inc.AIS
After Hours: 0.89 Down 0.00 (0.56%) 3:18pm ET
TEL AVIV (MarketWatch) -- Israel stocks were poised to end the month of June on a mixed note, with strength in Bezeq and Teva as well as certain technology stocks offset by weakness in the banks and Israel Chemicals.
The Tel Aviv Stock Exchange's benchmark TA-25 Index will change members beginning July 1, with Delek Group and Koor Industries joining the benchmark and Shufersal and Gazit Globe leaving.
Late in the trading day, the TA-25 Index fell 0.53% to 863.81, while the TA-100 Index /quotes/comstock/!ta100 (XX:TA100 811.85, +10.59, +1.32%) also declined 0.53%, to 805.64.
The Tel-Tech 15 Index of top technology issues edged higher by 0.21% to 197.28.
The most-active issue was telecom provider Bezeq, trading up 0.4%.
Teva Pharmaceutical /quotes/comstock/15*!teva/quotes/nls/teva (TEVA 49.70, -0.49, -0.98%) shares were next on the active list, up 0.7%. The Jerusalem drugmaker and a partner, Antares Pharma Inc., /quotes/comstock/14*!ais/quotes/nls/ais (AIS 0.88, -0.02, -2.01%) said the U.S. Food and Drug Administration cleared them to market the human growth hormone Tev-Tropin, generically somatropin, with a needle-free administration technology.
About
Antares Pharma, Inc. operates as a specialty drug delivery/pharmaceutical company. Its drug delivery platforms include Advanced Transdermal Delivery gels, disposable pressure assisted auto injection systems, reusable needle-free injection systems, disposable pen injection systems, and oral disintegrating tablets. The company?s transdermal systems consist of semisolid dosage forms, which deliver medication and minimize gastrointestinal impact, as well as the initial liver metabolism effect of orally ingested drugs. Its injection device platform offers reusable needle-free injectors, which deliver precise medication doses through pressurized liquid penetration of the skin without a needle; disposable pressure assisted auto injectors that provide subcutaneous injections with minimal discomfort and safety of a shielded needle; and disposable pen injectors, which are needle-based devices designed to deliver multiple injections from multi-dose drug cartridges. In addition, the company?s oral disintegrating tablets are designed to help patients experiencing difficulty in swallowing pills, tablets, or capsules. Antares Pharma sells its products through pharmaceutical and medical device companies primarily in the United States and Europe.
Last Trade: 0.89
Day's Range: 0.86 - 0.93
52wk Range: 0.29 - 1.21
Volume: 639,601
Here are a few alerts our WhisperfromWallStreet.com subscribers enjoyed.
SPNG 1000%
AMNG 241%
RKBD 300%
UTRM 169%
TLLE 266%
Sign up to receive free stock alerts
---
Disclaimer: Full disclaimer at http://whisperfromwallstreet.com/disclaimer.php
WhisperfromWallStreet.com (WFWS) based upon information believed to be reliable herein prepared all material. The information contained herein is not guaranteed by WFWS to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. WFWS is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on http://www.whisperfromwallstreet.com or mentioned herein. WFWS may have been compensated with shares or with cash from third party shareholders or the company on behalf of one or more of the companies mentioned in this opinion.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and WFWS undertakes no obligation to update such statements.
This is not a solicitation to buy or sell any securities. WhisperfromWallStreet.com, nor any of its affiliates are not registered investment advisors or a broker dealers. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.
CONTACT: WhisperFromWallStreet.com
